[NuTide:302] A Phase Ib/II open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
NuCana plc
Start Date
March 16, 2022
End Date
March 6, 2027
Administered By
Duke Cancer Institute
Awarded By
NuCana plc
Start Date
March 16, 2022
End Date
March 6, 2027